Compare Verisign, Inc. (VRSN) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Verisign, Inc. vs Zoetis Inc — how do they compare? Verisign, Inc. trades at $304.06 (market cap $26.92B), while Zoetis Inc trades at $74.76 (market cap $30.20B). The key difference: Verisign, Inc. and Zoetis Inc are close in size by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Verisign, Inc. for 123 Days and Zoetis Inc for 70 Days on average.
| VRSN | ZTS | |
|---|---|---|
Market Cap | $26.92B | $30.20B |
Volume | 1,921,402 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $310.00 | $147.53 |
52-Week Low | $211.49 | $69.09 |
Typical Hold Time | 123 Days | 70 Days |
Enterprise Value | $28.23B | $37.76B |
Dividend Yield | 1.09% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VeriSign (VRSN) trades at $303.74, up 3.24% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 49.77% net income margin and consistent revenue growth, reaching $1.66B in 2025. Recent news includes an upcoming Q3 2026 earnings call and insider selling by the CEO, while institutional buying from firms like BlackRock signals confidence. A class-action antitrust lawsuit filed in September 2026 poses a regulatory risk.
The investment outlook is positive, driven by analyst consensus favoring a buy rating with a $348 price target, implying 15% upside. Key opportunities include AI-driven domain growth and a pending .com price increase. Risks involve the antitrust litigation, competitive pressures, and reliance on domain registry revenues. Earnings momentum is mixed, with Q2 2026 missing estimates but Q1 beating expectations.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
